Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track BBIO with free AI briefings, catalyst countdowns, and dilution alerts.

BBIO · BridgeBio Pharma, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.5B Cash on Hand
80.1mo Cash Runway
12% Short Interest
$107 Analyst Target (20)
Follow BBIO by email Get an email when BBIO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about BBIO, unsubscribe in one click. Privacy

💊 Upcoming FDA Decisions

PDUFA DateDrugIndicationTypePoAOptions-implied move
2026-11-27 BBP-418 LGMD2I/R9 NDA 66% ±10% by Dec 18
2027-02-04 oral infigratinib achondroplasia NDA 66% ±19% by Feb 19
2027-05-08 encaleret ADH1 NDA 66% –

Options-implied move = price of the at-the-money straddle for the first option expiry after the PDUFA date, as a share of the stock price (Yahoo Finance quotes, Nov 17). It prices every move until that expiry, not only the FDA decision.

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →

📣 What BBIO Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

💰 Cash Runway & Dilution Risk

BBIO holds $1.5B in cash and short-term investments (as of Sep 30, 2026) and burns about $57.6M/quarter from operations, an estimated runway of 80.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 40 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BBIO files for a raise →

👥 Who Owns BBIO

Insiders 16.5% Other 5%+ holders 21.6% Institutions (649 holders) 61.9% Public and other holders 0%
HolderTypeShares% of sharesAs of
HALVORSEN OLE ANDREAS 5%+ holder (13D) 18,602,920 9.55% 2025-08-14
BridgeBio Pharma LLC
10% owner
Insider 14,589,846 7.49% 2025-10-10
Farallon Capital Management, L.L.C. Institution (13G, 5%+) 14,247,000 7.31% 2026-09-30
Farallon Capital Management LLC Institution (13F) 14,247,000 7.31% 2026-09-30
KKR Genetic Disorder L.P. 5%+ holder (13D) 13,260,971 6.81% 2025-05-12
JANUS HENDERSON GROUP PLC Institution (13G, 5%+) 13,179,013 6.77% 2026-03-31
Dapice Joshua J. 5%+ holder (13G) 10,226,063 5.25% 2026-05-22
BlackRock, Inc. Institution (13G, 5%+) 9,892,226 5.08% 2026-09-30
VIKING GLOBAL INVESTORS LP
10% owner
Insider 9,792,219 5.03% 2026-07-09
Wellington Management Group, LLP Institution (13F) 9,458,992 4.86% 2026-09-30
Kohlberg Kravis Roberts & Co. L.P. Institution (13F) 8,260,971 4.24% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 7,914,105 4.06% 2026-09-30

Share count 194,800,782 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-10-30
filed 2026-11-03
Apuli Maricel
Sale (S) 2,000 $72.85 120,687
2026-09-17
filed 2026-09-21
Kumar Neil
Sale (S) 8,721 $69.01 496,965
2026-09-17
filed 2026-09-21
Kumar Neil
Sale (S) 1,279 $69.57 495,686
2026-08-19
filed 2026-08-20
Kumar Neil
Sale (S) 1,800 $84.69 505,786
2026-08-19
filed 2026-08-20
Kumar Neil
Sale (S) 8,100 $83.86 507,586

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full BBIO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BBIO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.